BioNotebook: Merck drops Ariad's ridaforolimus; United Therapeutics, Infinity, Verastem updates; Dipexium, Achaogen IPO terms
This article was originally published in Scrip
Executive Summary
Ariad will regain ridaforolimus rights from Merck in November; United Therapeutics considers deals, protects patents; Infinity secures new debt; Verastem buys back VS-4718 rights; and Dipexium, Achaogen set IPO terms.